- Home
- OS vs LEGN Comparison
OS vs LEGN Comparison
Compare OS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OS
- LEGN
- Stock Information
- Founded
- OS 2012
- LEGN 2014
- Country
- OS United States
- LEGN United States
- Employees
- OS N/A
- LEGN N/A
- Industry
- OS
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- OS
- LEGN Health Care
- Exchange
- OS NYSE
- LEGN Nasdaq
- Market Cap
- OS 7.1B
- LEGN 7.8B
- IPO Year
- OS 2024
- LEGN 2020
- Fundamental
- Price
- OS $29.66
- LEGN $34.08
- Analyst Decision
- OS Strong Buy
- LEGN Strong Buy
- Analyst Count
- OS 19
- LEGN 13
- Target Price
- OS $35.67
- LEGN $81.54
- AVG Volume (30 Days)
- OS 1.1M
- LEGN 1.5M
- Earning Date
- OS 02-15-2025
- LEGN 11-12-2024
- Dividend Yield
- OS N/A
- LEGN N/A
- EPS Growth
- OS N/A
- LEGN N/A
- EPS
- OS N/A
- LEGN N/A
- Revenue
- OS $459,526,000.00
- LEGN $520,183,000.00
- Revenue This Year
- OS $33.26
- LEGN $120.77
- Revenue Next Year
- OS $20.42
- LEGN $68.54
- P/E Ratio
- OS N/A
- LEGN N/A
- Revenue Growth
- OS 64.51
- LEGN 122.96
- 52 Week Low
- OS $24.50
- LEGN $32.50
- 52 Week High
- OS $35.39
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- OS N/A
- LEGN 31.74
- Support Level
- OS N/A
- LEGN $32.50
- Resistance Level
- OS N/A
- LEGN $35.08
- Average True Range (ATR)
- OS 0.00
- LEGN 1.98
- MACD
- OS 0.00
- LEGN -0.51
- Stochastic Oscillator
- OS 0.00
- LEGN 13.10
About OS ONESTREAM INC
OneStream Inc is an AI-enabled and extensible software platform that unifies core financial functions and broader operational data and processes within a single platform. The Digital Finance Cloud of the company provides a comprehensive, dynamic, and predictive view of the entire enterprise, providing corporate leaders the control, visibility, and agility required to proactively adjust business and day-to-day execution.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.